All stocks / AURX
Nuo Therapeutics, Inc. AURX
Nuo Therapeutics (AURX): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- NUO THERAPEUTICS INC
- Market tier
- OTCQB
- Trading status
- Active
- Last trade
- Nov 16
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Net loss
- ($2,512,216)
It spends more than it earns
Under strainThe company lost $2.5 million in the year. It reported no sales.
- Cash and cash equivalents
- $548,946
- Net cash used in operating activities
- ($864,971)
The cash could run out soon
Under strainIt had $548,946 in the bank and used about $72,081 a month. At that pace the money lasts about 8 months unless it borrows or sells more shares.
- Total assets
- $1,845,662
- Total liabilities
- $2,802,221
It owes more than it owns
Under strainEverything the company owns adds up to $1.8 million. Its debts and unpaid bills add up to $2.8 million. That is about $1.52 owed for every $1 owned.
What this adds up to
3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 40,833,853 shares as of 2026-11-12: 48,585,593 outstanding minus 7,751,740 held by 4 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about AURX
Does AURX file reports with the SEC?
Yes. Nuo Therapeutics files with the SEC under company number 0001091596. The most recent filing we hold is a 10-Q dated 2026-11-13.
Source recordHow many AURX shares are outstanding?
48,585,593 shares as of 2026-11-12, as reported to the SEC.
Source recordHas AURX filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs Nuo Therapeutics?
Officers named in its insider filings: Peter Clausen (CSO/COO) and David Emerson Jorden (CEO/CFO).
Source recordIs Nuo Therapeutics making money?
The company lost $2.5 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record